Scholarlink

<p>Cancer remains a pressing global health concern, burdening individuals, families, and healthcare systems worldwide, mainly because of the limited availability of therapeutic options. These days, nanotechnology is revolutionizing cancer research by offering promising drug delivery systems. Among these, nanobots and nanocarriers are key nanotechnology components, offering groundbreaking strategies in cancer therapy by delivering drugs, enhancing diagnostics, and preventing diseases at molecular levels. Nanobots&#xa0;and nanocarriers, engineered at sizes ranging from 1 to 100&#xa0;nm, demonstrate biocompatibility with cellular systems, offer precise drug delivery, and reduce side effects compared to conventional therapies such as chemotherapy and surgery. Research efforts now focus on transitioning nanobots and nanocarriers from laboratories to clinics, aiming for precision medicine, targeted drug delivery, enhanced therapy efficacy, and minimal side effects. This review aims to highlight the potential of nanobots and nanocarriers in cancer treatment and provide insights into&#xa0;their role in paving the way for clinical applications and improving outcomes in cancer therapy.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic applications of nanobots and nanocarriers in cancer treatment

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月4日

查看全文
  • Zaitoon Khan,
  • Nimra Khan,
  • Mithra Geetha,
  • Reyhanath Pilakka Veettil,
  • Deepak Mahadev Kasote,
  • Anwarul Hasan,
  • Kishor Kumar Sadasivuni

摘要

Cancer remains a pressing global health concern, burdening individuals, families, and healthcare systems worldwide, mainly because of the limited availability of therapeutic options. These days, nanotechnology is revolutionizing cancer research by offering promising drug delivery systems. Among these, nanobots and nanocarriers are key nanotechnology components, offering groundbreaking strategies in cancer therapy by delivering drugs, enhancing diagnostics, and preventing diseases at molecular levels. Nanobots and nanocarriers, engineered at sizes ranging from 1 to 100 nm, demonstrate biocompatibility with cellular systems, offer precise drug delivery, and reduce side effects compared to conventional therapies such as chemotherapy and surgery. Research efforts now focus on transitioning nanobots and nanocarriers from laboratories to clinics, aiming for precision medicine, targeted drug delivery, enhanced therapy efficacy, and minimal side effects. This review aims to highlight the potential of nanobots and nanocarriers in cancer treatment and provide insights into their role in paving the way for clinical applications and improving outcomes in cancer therapy.

Graphical abstract